Pages

Wednesday, June 27, 2012

Nanotechnology is to the 21st Century what chemistry was to the 20th Century


June 27th, 2012
by 


The word "nanotechnology" gets thrown around a lot but it still remains a fuzzy concept for most people.

From a self-aware, self-assembling grey goo that takes over the world in a Michael Crichton book, to Apple's (Nasdaq: AAPL) Nano music player or Tata Motor's (NYSE ADR: TTM) Nano car, it's hard to get a clear picture of what nanotech really is.

But as global World Economic Forum member and emerging tech guru Dr. Tim Harper explains, "Nanotechnology is to the 21st Century what chemistry was to the 20th Century."

Like plastics, computers, and the Internet before it, nanotechnology will change the world in ways that we can't even imagine now. That's how powerful the nano-world will become.

That's why every long-term growth investor needs to consider investing in nanotechnology. In terms of scale, the potential for investors is simply enormous.

That's why one company, FEI Co. (Nasdaq: FEIC) is on my list of "buys" as the top "picks and shovels" play.

The Miracle of Nanotechnology

So what exactly is nanotech?

It's a way of working with objects and materials at the atomic level, one molecule at time.

That means that in the near future, we will be able to custom design structures literally from the ground up, molecule by molecule, creating a quantum leap forward in medicine, materials, electronics, food, and fuels - practically everything we know of.

In fact, one of the biggest sectors where nanotech continues to have a huge impact is in drug development and drug delivery.

Recent nanotech developments include: cancer treatments without chemotherapy or radiation, long-dose treatment of diabetes with a single monthly injection, long-release or on-demand blood pressure medications, and textiles to build skin, bone or organs from you own cells.

Developments like these will invariably lead to big money

A recent report by Cientifica, a leading global emerging technology consulting firm predicts:
  • Nanotech-enabled drug delivery therapeutics is set to grow from a current value of $2.3 billion to $136 billion by the year 2021.
  • Global growth in the drug delivery market will be led by Asia with a compound annual growth rate (CAGR) of 32.5% between now and 2021.
  • And the total addressable market for nanotech enabled diagnostics will reach $53.6 billion in 2021 from $2.4 billion in 2011.
But drug delivery is just a small piece of the sector. The truth is nanotech is going to impact every facet of your life someday.

Because if you look into every industrial sector from textiles to materials to electronics to energy to defense to computing to telecommunications to packaging, nanotech is the fulcrum that is moving the world.

Investing in Nanotechnology: The Leading Player in the Game

For investors that opens up a whole new set of opportunities.

And if there is one thing this new field requires, it's the ability to see what's happening to these materials at these elemental levels.

That means high-powered microscopes and scanning equipment are the picks and shovels of today's (and tomorrow's) innovators.

And when it comes to these devices, FEI Co. is one of the leading players in the game.

A five-year price chart of FEIC is a simple story of how integral modern day microscopy is to the new economy. Since cratering around 11 in early 2009, the stock has had a steady rise to around $50 today.


As you can see, even as the world financial system crumbled, the world entered the Great Recession, FEIC kept chugging along.

Part of the reason was healthcare was a pretty stable base for the company as companies poured money into new R&D projects.

But FEIC also has a Natural Resources Business Unit that does imaging for energy companies around the world, including spotting shale reserves.

As cheap oil dwindles and unconventional oil and gas become the norm, FEIC's QEMSCAN imaging system will become even more in demand. In fact, earlier this month the company announced a fee-based agreement with a major oil service company to provide on-site automated surface logging using the QEMSCAN WellSite analysis solution for a U.S. customer.

So there's little doubt this unit will be pumping a lot more revenue into the company as the years progress. It has contracts in every major oil developing country in the world already.

As for business in general, revenue is up, margins are up and net bookings are up-- all in a terrible global economy.

New electronics, new textiles, new materials, new drugs, new energy -- FEIC will be in the middle of it all.

FEIC is a "Buy" up to $50.

Source: Investing in Nanotechnology: FEI Co. (Nasdaq: FEIC) is the Top "Picks and Shovels" Play:

Friday, June 22, 2012

Penny Stock Tech Investing: Avoid Pitfalls and Position for Profits

June 22, 2012
by 
www.moneymorning.com

Penny-stock traders are like the Rodney Dangerfield's of the investment world - they get no respect from their bigger brethren. But that doesn't mean they should be ignored. Fact is, while penny stock investing can be risky, it can also be extremely lucrative. Some of the most successful investors in the world became rich buying stocks for pennies on the dollar and selling for $10 or $20 a share.

The key to success is to fully understand all those risks...avoid them at all costs... and then make the right moves so you can safely realize the big profits. Let me explain...

Penny Stock Basics

So-called "pennies" get their name from their low price. They typically trade for less than $5 a share. (And many trade for true pennies, with share prices well under a dollar.) The SEC generally defines them as securities from small companies, most of which trade on the Over-The-Counter-Bulletin Board (OTCBB) and Pink Sheets, LLC. Both have minimal listing requirements. The fact that penny stocks aren't regulated (especially on the Pink Sheets) can be nerve-racking to some.

But it's overly cautious to think of penny stock trading as the Wild Wild West of the financial world. Keep in mind that fraudulent misrepresentation of financials is a Federal offence no matter where a company's shares are listed. Nevertheless, penny stocks have much fewer shareholders than a typical SEC-regulated stock.

The good news for you is that this lack of liquidity makes it much easier for the share price to spike with a major shift in trading. For example, a gain of just six cents for a 30-cent stock means a 20% jump in valuation, whereas a 6-cent gain for any stock trading on the New York Stock Exchange wouldn't turn many heads.

Bottom line: While penny stocks are very volatile in the near term... (they can plunge just as fast and they can skyrocket)... it's the very same volatility that gives them such a hellacious upside -and makes them one of the best wealth-creating categories of stocks you'll find anywhere.

How To Tell The Genuine Article From The Imposters

Penny stocks are plentiful - about 6,000 of them are available today. Trying to sort through all of them can be daunting. That's why I created three "buckets" to help organize and categorize them.

Bucket 1: "Penny Diamonds" Micro-Cap Gems With High Growth Potential

If you're looking for a tiny, virtually unheard of company with a new technology, product, service or drug that's poised for a big breakthrough, the OTCBB or the Pink Sheets is the place to start. As I mentioned, companies that are involved in this kind of over-the-counter trading fall just outside of the many regulations that restrict the activities of the major stock exchanges. That means they don't adhere to many of the time-consuming accounting and finance regulations of the SEC.

But to make traders more comfortable, Pink Sheets LLC recently created a new classification system to help investors assess the legitimacy of the companies in their roster. The highest is called "PremierOX." Companies under this classification must sell for at least $1 a share, have at least 100 shareholders with a minimum of 100 shares each... AND meet the requirements of all the major exchanges. The second level is called PrimeOX. There is no minimum share price here but companies must have at least 50 shareholders with a minimum of 100 shares to gain entry. There are other classifications - including the legitimate OTCQX for international companies. The complete hierarchy can be found at the Pink Sheets Web site.


But generally speaking when looking for those "Penny Diamonds" you should stick to the top two tiers. Of course, finding the "next big thing" is not going to be easy. It won't just pop out and announce itself to you. That's why research is imperative. Do your homework. Here are some rules of thumb:

  • Always review the company profile on Pink Sheets and the company's own website.
  • Always request information directly from the company you're interested in. Whether by phone or e-mail, get in touch with a representative of the business and request any information they can send you - whether it is about their finances, their products or, if overseas - the political, economic and social situations in their countries. Risk assessments and future opportunities - anything you need to know to be sure of a company's potential - are also important.
  • Do not even consider a company that isn't forthcoming with their information. Be wary of companies that will not consider treating the interests of their minority shareholders as their own.
  • If the company you're researching is outside the U.S., you should also research the business laws inside the company's home country.
Once your homework is done, it's time to look for a catalyst. A catalyst can be any type of event, date, or unique situation that could create a spark that'll send your share price soaring. Here are two big catalysts to look for:


Ready For Market:

Many penny stock companies (particularly health related biotech's or innovative technology companies) spend years researching and developing their products. This may include lengthy and rigorous testing. Pharmaceutical biotech products can spend years in trials and tests.

The catalyst occurs when the company is ready to go to market. Look for the end of trial dates... or actual roll-out dates. That means the company is ready to manufacture and sell its products and services. For biotech's, it also could mean a promising drug is nearing FDA approval.

Buyout Candidates:

Many small companies are prime buy-out candidates. Typically these companies have a market niche, a technology, a promising drug, product (even patents) that a larger competitor desires. When one company buys another, they agree on a price. Many times, that price is much higher than with the penny stock's company's price is currently trading. This gives those shareholders an instant gain.

My advice is to follow Merger & Acquisition (M&A) trends to see what sectors are hot. For example, record-breaking M&A activity is occurring in the pharmaceutical biotech sector right now.

That's because big drug makers risk losing $170 billion in annual sales when patents expire on their most lucrative drugs. So they're battling back, embarking on a multi-billion-dollar shopping spree, buying up small players who can replenish their pipelines.

Imagine if you buy a sensational penny stock biotech for under a dollar and the company gets bought up by Big Pharma. It's practically guaranteed that you'll see sizeable gains.

Bucket 2: Fallen Angels

Not all penny stocks are unknown companies traded over the counter. There are also companies that already have their fair share of recognition... perhaps even trading on the major exchanges... but whose stock price is under $5.

Some of these companies I call Fallen Angel's. A Fallen Angel is a high quality company whose stock price has declined due to market forces out of their control. For example, a company may lose market share due to a business and economic cycles in their particular industry... a recession... or even a market crash. Some of these companies have very strong fundamentals, still trade on the major exchanges, and offer very substantial upside.

In short, a Fallen Angel gives you a tremendous value play, selling at significant discount to their intrinsic value and represent terrific bargains. At the end of this report, I'll tell you one of my current favorite Fallen Angels.

Bucket 3: Shell Companies

Pink sheets are often sprinkled with "shell" companies that exist on paper but have no assets. They simply exist for one purpose: To inflate their stock price and cash out. These are the penny stocks you need to avoid at all costs. How do you recognize and avoid these types of stocks?

I provide details about penny stock traps and scams below... but keep this in mind: Many of these companies resort to tactics such as high pressure telephone calls, email marketing schemes and phony promotion ploys that try to convince you their stock is about to go through the roof. The truth is, most of these marketing schemes are run by professional promoters who make a good living spreading rumors about penny stocks Often these illegitimate companies could see their stock ramp up... then instantaneously drop 50, 60, even 100%.

Pump And Dump

The most common type of penny stock scheme is called the "Pump and Dump." This scheme has been an investor pitfall to avoid the penny stock world for a long time. A classic "Pump and Dump," works like this: A holder of a big block of penny stock shares orchestrates a "whisper campaign" to pump up a penny stock company and its product. Traders rush in, driving the price skyward, enabling the perpetrator to "dump" his shares at a big profit. Those left "holding the bag" lose big time.

Here are some signs to watch out for:
  • Penny stocks that have "guaranteed performance." ( There's no such thing)
  • Penny stocks that have extremely low volume. (It's impossible to tell where this stock is heading, making it even more risky than most)
  • Penny stocks that you hear about from friends, at the office, over the phone or a social venues (These are typically stocks being pushed by talented marketers)

Tips On Investing In Penny Stocks Safely

You can avoid the common penny stock pitfalls pretty easily. Here are some safety tips. First, remove the dollar signs in front of your eyes and replace them with company research. Start by looking for companies with financial track records, an important screen that eliminates 95% of the "shell" penny stock companies out there. Be a skeptic.

In other words, dig deep to make sure the company is sound and their business make sense.

Once you decide on a company, you should "know" that company inside out. Know what it does... how it does it... how it makes money... and especially its management. Second, apportion only a small amount of your overall portfolio to penny-stock investing. That means that you can't clutter your mind with a lot of "what if" long-shots - such as, "what if this stock soars...I'd be able to buy a vacation home or retire rich by 49." That kind of financial sobriety sounds boring, but sobriety today means there's no hangover tomorrow. Once you have thoroughly researched your stock of choice and purchased it through your broker or online, be prepared to treat it as a long-term investment.

These stocks are smaller companies that are not constantly watched by analysts and regulators. They can sometimes go days without even a single share changing hands. This will no doubt make some of the nail-biters out there anxious. But most intelligent investors find it liberating to be able to forego the short-term roller-coaster ride and focus on growth potential over the course of a company's natural life.

That doesn't mean ignore your investments altogether. Make sure you keep up with the information coming from the company and any third-party news stories - just like you would with an investment on a traditional exchange. But don't sell just because you don't see a change over a few hours or days.

Finally, don't get greedy. If you realize big gains on a stock at first, you could still end up losing money. You need to understand not only when to get in... but when to get out.

Here's A Great Penny To Get You Started...

You can start building a penny stock portfolio right away. I've chosen a small-cap stock - one that I feel has substantial potential and already trades on a major exchange. Yes, it's been spotted by Wall Street, but its stock is still cheap.

The company is New York-based biotech Delcath Systems (Nasdaq: DCTH), one of my Fallen Angels. Founded in 1988, Delcath makes specialty medical devices. It is developing a proprietary system for chemosaturation. The company's plan is to administer high-dose chemotherapy and other therapeutic agents directly into diseased organs or regions of the body, while controlling the systemic exposure of those agents. This chemotherapy "targeting" lets doctors deliver much stronger doses to the affected area. And it protects the rest of the body from chemotherapy's dangerous side effects. Delcath just reported progress at a recent meeting of the American Society of Clinical Oncology (ASCO).

The company has a solid business plan contained in a new investor presentation you can get by clicking here. At 105 pages, it's thorough to say the least. And it has a brand new catalyst working in our favor: It just announced a second-generation use of its product and filed an amendment with the FDA.

Delcath's stock price is currently under $2 a share. Its stock pulled back a bit because of recent volatility in the market. But unlike many small caps which are riddled with debt, this company is sitting on $31 million in cash. It may be a micro-cap but it offers major profit opportunities. And the stock price has held up well after the company issued $20 million in new shares and warrants to the public, meaning we can get shares at pretty close to rock bottom. I believe it's an excellent choice to get you off to good start in penny stock investing.

I've also recently put together another report report that focuses on some incredibly interesting technology stocks. Several of these, I believe, will change the way we do business for decades to come. To see this full report, just go right here.

Source: Penny Stock Investing: Avoiding Pitfalls and Positioning for Triple-Digit Profits:

Thursday, June 21, 2012

Special Report from the ADA: William Plovanic Identifies Companies with Promising Diabetes Solutions, Prospects


By The Life Sciences Report Editors  (6/21/12)
William PlovanicEvery year, top researchers and physicians meet at the American Diabetes Association Scientific Sessions. This year, Canaccord Genuity Analyst and Managing Director William Plovanic reported back on promising developments and what they could mean for the companies behind them. In this interview with The Life Sciences Report, he explains why he is so positive on the space in general and about certain companies in particular.


The Life Sciences Report: You recently attended the 72nd Annual Scientific Sessions put on by the American Diabetes Association (ADA) in Philadelphia. What were the major takeaways?

William Plovanic: We attended scientific sessions and spoke with a number of management teams. Overall, we came away with clarity on new product introductions across the three major growth categories: continuous glucose monitoring (CGM), hospital continuous glucose monitoring and insulin pumps. We were also encouraged by management feedback as it related to U.S. Food and Drug Administration (FDA) interaction and projected regulatory timelines for next-generation products.

TLSR: What did you learn about continuous glucose monitoring?

WP: The conference had a significant CGM focus, which is encouraging as we believe the FDA logjam appears ready to break open. The data continues to shine positively on CGM, reinforcing our belief that the current and next-gen technologies will become standard of care. It is still our belief that CGM will be the gold standard for type 1 diabetes.

TLSR: What was new in the hospital CGM space?

WP: In-hospital CGM remains a large market opportunity—we estimate +$1 billion in the U.S. alone. However, getting these products through the FDA continues to be challenging. The FDA needs to set its standards and expectations before U.S. pivotal trials can move forward for devices in this space. Furthermore, given the complexities of measuring glucose in intensive care units (ICUs), we remain cautious as there is little to no prospective data in the intended-use population base.

In a nutshell, most of these products are still "research projects." As a result, companies are targeting the European Union as the first market for commercialization. From our conversations, it appears the players have shifted positions, with OptiScan (private) beginning measured European commercialization, GluMetrics Inc. (private) deep in a large intended-use clinical trial, and DexCom Inc. (DXCM:NASDAQ) ($11.56/Buy) working out the next step with Edwards Lifesciences Corp. (EW:NYSE).

"We were encouraged by management feedback as it related to U.S. Food and Drug Administration interaction and projected regulatory timelines for next-generation products."
DexCom seems to be making progress on approval of its G4 CGM system. Management indicated at the conference that it could be given the nod before year-end 2012, which is ahead of our first half of 2013 estimate. The company could start a pediatric study in the next quarter to facilitate label expansion. Early snippets of G4 data looked positive, with single-digit mean absolute relative differences (MARDs) realized in day two of sensor usage, which is a major improvement from the mid-teens for Dexcom's Seven Plus unit.

Another company, Echo Therapeutics Inc. (ECTE:NASDAQ) ($1.69/Not Rated) is developing the Prelude SkinPrep and Symphony tCGM systems, which together form a transdermal CGM system. The systems are noninvasive and continuously collect data and wirelessly transmit it every minute to a remote monitor. Management plans to target the in-hospital market first. We believe the system is ideally geared more for the ward rather than the ICU or step-down unit. Like most products in the space, we are aware of very little to no prospective data on intended-use patients.


TLSR: What developments did you see in the insulin pump space?


WP: 2012/2013 is set to be a year of new market entrants, with multiple competitors moving toward commercialization and entering the U.S. market. We are excited to see different competitors target specific market segments within the pump market.

We continue to be bullish on Insulet Corp. (PODD:NASDAQ) ($19.80/Buy), as we would not expect the new competitors to impact Insulet's market share or win rate of new pumps. Insulet management provided an update on the current regulatory status of its next-gen insulin pump (Eros), noting it had received only a handful of questions from the FDA. Commentary led us to believe the questions were "drill-downs" into previous questions rather than anything unexpected. Management noted an expectation that answers would be submitted within the next week or two, positioning the company on track for approval in the next quarter or two.

The current agreement with Abbott Laboratories (ABT:NYSE), pairing its glucose test strip with Insulet's pump, expires in March 2013 and Insulet has already entered into a nonexclusive agreement with Animas Corp. (a Johnson & Johnson [JNJ:NYSE] company). We will be watching the outcome of these agreements in 2012, as Insulet will pick the company that will benefit from its huge installed base of high-volume strip customers. On the CGM front, its partnership with DexCom is moving forward. Insulet remains very focused on integrating DexCom's G4 sensor into its OmniPod (think of an OmniPod with a cannula at each end). We believe a product in this configuration would offer Insulet a differentiated product relative to the competition.
Valeritas Inc. (private) was profiling its V-Go, a simple one-day pump for type 2 insulin-dependent patients. It is an evolutionary pairing of the patch pump and insulin pen. The V-Go is a completely mechanical basal-bolus insulin delivery device designed as a disposable, one-day-wear device. V-Go delivers a preset basal rate (0.83, 1.25 or 1.67 units per hour) and on-demand bolus (two units) dosing. Valeritas is positioning the product with a different approach to reimbursement, taking the pharmacy benefit route that current insulin pens use. The company is well funded, with $150 million raised in September 2011.
"The fact that it is an election year might have something to do with a more rational (if not more reasonable) FDA."
The company had a large presence at the conference, with a busy booth and a very well-attended product theater showcase. We'll keep our eyes on this one, as its slick design and touch-screen interface are sure to catch the eye of users. That said, it is a tethered pump, and as such should not impact Insulet. Instead, it could target the market leaders Medtronic Inc. (MDT:NYSE) ($37.03/Not Rated) and Animas.
Asante Solutions Inc. (private) did not have a booth at the conference, but we met with management and got our hands on the Pearl, the company's new modular insulin pump that uses prefilled insulin cartridges. The product is expected to begin controlled commercialization by year-end 2012. Asante will also go the pharmacy benefit route and utilize the tethered pump in a pay-as-you-go model.


TLSR: Who else did you visit at the conference?


WP: Medtronic submitted a premarket approval (PMA) application to the FDA for its 530G combo CGM/pump (called the Veo internationally). The system features low-glucose suspend technology as well as the new six-day Enlite sensor, which was highlighted as having an overall MARD of 13.6% across six days of readings in type1/type2 patients. Given FDA timelines and the multiple rounds of questions seen with DexCom's and Insulet's latest filings, we believe the application is likely to take at least a year. If approved by the FDA, the MiniMed 530G system will be the only integrated insulin pump and continuous glucose monitor in the United States that automatically suspends insulin delivery if the sensor glucose value is equal to or below the low threshold value. Medtronic's PMA submission includes data from the in-clinic ASPIRE (Automation to Simulate Pancreatic Insulin Response) study, which met its efficacy endpoints. The study showed a reduction in time spent below the low-glucose threshold in people with diabetes using the Threshold Suspend Automation feature, as compared to conventional pump therapy. The in-home ASPIRE study is still ongoing.
The company is also working toward a six-day approval for its new Enlite Sensor, which is currently in the regulatory process at the FDA. Reported results showed an overall 13.6% MARD over six days of readings in type1/type2 patients.


TLSR: You said that you left feeling positive about the diabetes space. Why?


WP: We came away from the conference with the impression that there is a stronger interest in the space. We were bolstered by the innovative technologies showcased and encouraged by feedback about regulatory timelines from management. The fact that it is an election year might have something to do with a more rational (if not more reasonable) FDA.

William Plovanic joined Canaccord in 2007 as managing director, medical technology equity research analyst. He has been a publishing sell-side analyst with coverage of medical devices for more than 15 years. Plovanic's areas of coverage include orthopedics, diabetes, obesity, neuro-technologies, dialysis, aesthetics and general surgery. In 2009, Plovanic was ranked as the #2 earnings estimator for healthcare equipment and supplies by StarMine. In 2003 and 2004, Plovanic was selected as a Wall Street Journal "All Star" analyst in the medical device sector and in 2002 was named the #1 analyst by StarMine for stock-picking and performance in the medical technology sector. Plovanic is a frequent presenter at medical and industry meetings. Prior to joining Canaccord, Plovanic was a managing director and senior research analyst at First Albany (now Gleacher & Company). Previously, he worked at PMG Capital covering medical devices and products. He also worked as director of research for the capital markets division of LaSalle St. Securities LLC, where he focused on the small-cap healthcare, technology and biotechnology industries. He graduated from Bradley University with a bachelor's degree in finance and is a chartered financial analyst.

Want to read more exclusive Life Sciences Report interviews like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see a list of recent interviews with industry analysts and commentators, visit our Exclusive Interviews page.


DISCLOSURE:
1) The following companies mentioned in the interview are sponsors of The Life Sciences Report: Medtronic Inc. and Johnson & Johnson. Johnson & Johnson and Medtronic Inc. are not affiliated with Streetwise Reports. Interviews are edited for clarity.
2) William Plovanic: I personally and/or my family own shares of the following companies mentioned in this interview: None. I personally and/or my family am paid by the following companies mentioned in this interview: DexCom Inc., Insulet Corp. and TranS1 are investment banking clients of Canaccord Genuity Inc. Additional information, including disclosures regarding all securities under research coverage, is available at http://www.canaccordgenuity.com/en/ODD/pages/disclosures.aspx. I was not paid by Streetwise Reports for participating in this story.

( Companies Mentioned: DXCM:NASDAQ, ECTE:NASDAQ, PODD:NASDAQ, JNJ:NYSE, MDT:NYSE)

Source: Special Report from the ADA: William Plovanic Identifies Companies with Promising Diabetes Solutions, Prospects:

How the Apple (Nasdaq: AAPL) iPhone Will Save Millions of Lives-and Make Early Investors a Bundle

Michael A. Robinson, Defense and Technology Specialist
www.moneymorning.com

It's hard to believe, but it's true. The iPhone turns five years old next week.

Since its official launch on June 29, 2007, Apple Inc. (Nasdaq: AAPL) has sold well over 180 million iPhones. Hands down, it's the most successful mobile phone ever launched.

But what most investors don't realize is the huge impact the iPhone has had on medicine.

The fact is, more than any other product on the planet, the iPhone is driving a whole new sector called mobile healthcare, or mHealth for short. With an iPhone in hand, it will redefine how doctors and other health-care pros work with their patients.

But here's the big payoff: mHealth promises to save millions of lives as doctors use it to detect and treat diseases much more quickly than they could with old-school devices. These radical advances will undoubtedly make lots of early mHealth investors quite rich.

But don't take my word for it....

A trade group known as GSMA says the mobile healthcare sector will reach total sales of $23 billion by 2017.

Of course, phones and tablets that use Google Inc.'s (Nasdaq: GOOG) Android operating system also could play a big role in the sector. But at this point the iPhone remains the clear leader in this rapidly growing market.

It's So Much More Than a Phone

That's why I'm glad to introduce you to a startup firm that has staked much of its future on the iPhone platform. It's a company called AliveCor. Indeed, the bet has paid off so far.

Fact is, AliveCor recently raised another $10.5 million in venture funding. That brings the total raised to date to roughly $13.5 million. The company first made waves last year when it showed off its iPhone-based heart monitor at the Consumer Electronics Show in Las Vegas. Since then, AliveCor has applied to the FDA to sell it as an approved medical device.

The Alivecor product allows professionals and consumers to monitor the heart health of a person or even an animal. Its heart-tracking technology is designed to work with the iPhone, iPad and Android devices. In technical terms it's a mobile electrocardiogram (ECG) recorder. That means it measures the heart's electrical activity.

Doctors use this test to see if there are any problems with the heart they can't detect with a simple office visit. For instance, an ECG will show if the heart is not beating with the correct rhythm, which could indicate a disease or other problem. Product reviews say the AliveCor ECG will cost just $100, adding that the product is easy to use. When heart patients want to record their ECG, they open the app and hold the phone to their chests. In the blink of an eye the app shows the results. It records 300 samples per second. When finished, the app can upload the patient's ECG to AliveCor's servers. Doctors can then review the tests from just about anywhere in the world using a Web browser in a secure format. The firm says the results match those of much more costly clinical-grade gear.

Last month, AliveCor cited a study in which two doctors cross-checked the results against standard monitors in more than 60 patients. The iPhone platform proved just as accurate at a fraction of the cost, the company says. You can view of video of the device in action here.

The Market for These Apps Is Huge

AliveCor is already targeting what could be a huge market. You see, health stats show that heart disease remains the leading cause of death in the U.S. It claims nearly 600,000 lives a year. Many could have been saved had they seen a doctor before disaster struck. AliveCor's ECG would allow millions to track their heart health themselves.

Look at it this way. If the AliveCor ECG caught just 20% of the potential cases, it could save more than 1 million lives over the course of a decade. Not only that, since it allows for fewer doctor visits, the iPhone approach could have a big impact on healthcare costs. Consider that the American Heart Association predicts that by the year 2030, the cost of heart disease will more than triple to $818 billion a year.

By then, 116 million people in the U.S., or about 40%, will suffer from some form of heart disease. But remember, we've just covered one product targeting a single disease. No doubt the iPhone will find uses in many other medical applications. Taken together, these new apps will save millions of lives and help transform medical science as we know it. All it takes is cutting edge products like an iPhone and the genius of thousands of creative entrepreneurs.

When you have that there's no limit to how far you can go.

Cheers,

Michael A. Robinson, Defense and Technology Specialist

P.S. If you want to find a way to profit from the next generation of tech breakthroughs, Michael's Era of Radical Change newsletter is a great place to start.

And you can't beat the price. You can get it free by clicking here.

Further Reading....

Michael A. Robinsonis one of the top financial analysts working today. In fact, he recently called out the Wall Street Journal for what he said was "some bad and very misguided press" about the future of asteroid mining.

To find out why Michael says the Wall Street Journal is dead wrong about asteroid mining click here.
About the Author


Michael A. Robinson is one of the top financial analysts working today. His 30-year track record as a leading tech analyst has garnered him rave reviews. The first analyst to uncover the rare earth mineral crisis, he amassed cumulative gains of 990% for his readers in just 16 months. Today he is the editor of Radical Technology Profits. He also edits the Era of Radical Change e-letter that explores "what's next" in the tech investing world. Learn more about Michael on our contributors page.


View

Source: How the Apple (Nasdaq: AAPL) iPhone Will Save Millions of Lives-and Make Early Investors a Bundle:

Tuesday, June 19, 2012

These Teen Geniuses are on a Path to Change the World

By Miichael Robinson for Money Morning
www.moneymorning.com

He's barely old enough to shave... but Jack Andraka is already hard at work helping America win the war on cancer.

Just last month, the Baltimore-area whiz kid took top honors at a key contest hosted by Silicon Valley legend Intel Corp. (NasdaqGS: INTC). He invented a low-cost, cutting-edge cancer screen that could save thousands of lives every year.

Andraka now ranks as a rising star and radical change agent who could have a huge impact on high tech and medicine. He also pocketed a cool $100,000 in prize money.

And all at the ripe old age of 15...

He's one of the reasons why I say it pays to remain upbeat about America's future. He and these six other youngsters I'm about to tell you about demonstrate how much innate talent we have in this country, and I believe that's one reason why we can't help but succeed in the long run.

Don't get me wrong. America faces big challenges - rising debt, chronic job losses, and political gridlock, to name but a few.

Yet we're also the one country that steadily produces bright young entrepreneurs who change the world around them. Where others see obstacles, these teens see opportunities.

They go on to launch the Googles, Apples, and Microsofts of the world, and they leave a trail of wealth behind them.

As investors, we want to spot this talent before others do. That's how we maintain the inside edge that vaults us ahead of the pack when new investment opportunities come along.

Fact is, kids today may not be any smarter than the Edisons and Fords of their day. But in the Era of Radical Change, they have the tools - sensors, computers, software and more - that scientists of old could only dream about.

Today, I want to introduce you to the seven young geniuses who are pushing the limits of science and high tech.

I've drawn their names from the list of winners of two recent contests sponsored by Intel. Here's the thing. Some seven million high school kids from around the world compete in science contests each year. Only a handful makes it to the top of these elite events.

That's why I think we need to start paying attention to these seven young geniuses today.

Teen Geniuses No. 1 and No. 2: The Andraka Brothers

I've already told you about Jack Andraka. His big brother Luke is no slouch, either. He won that same Intel International Science and Engineering Fair (ISEF) award two years ago for a project that looked at how acid mine drainage affects the environment. But certainly no one could accuse Jack of living in his big brother's shadow. He won the 2012 grand prize that paid $75,000 and picked up other awards worth an extra $25,000. Jack came up with a simple dipstick sensor that can spot a key marker that shows the presence of cancer. Intel execs say Jack's sensor is both 28 times faster and 28 times cheaper than current tests. It may even come to market someday - Jack has already applied for a patent.


Their mother says the boys spend little time with sports. They do have tons of science magazines lying around the house. The family often talks about big ideas and how people can do things in new ways.

Teen Genius No. 3: Ari Dyckovsky

An 18-year-old from Leesburg, Va., Ari Dyckovsky took a very esoteric field of science and used it to improve cyber security. He found that that once atoms are linked together through a process called "entanglement," data from one atom can simultaneously appear in another atom.

Using this method, groups that need high levels of network security could send encrypted messages long distances without the risk of theft. That's because the data wouldn't need to "travel" to its new location; it would simply appear there.

Teen Genius No. 4: Nicholas Scheifer

OK, there's one guy on the list who doesn't live in America. Turns out he's Canadian and hails from the Toronto area. But like many foreign-born high-tech whizzes, he made his name right here in the Good Old USA.

Nicholas Scheifer, 17, claimed the ISEF $50,000 second prize this year. Turns out his hunch about how to improve search-engine results was correct. He tweaked standard queries so they would work better in a mobile world that values shorter texts, like those from Twitter and Facebook. "The issue is how to make search engines understand the subtlety of words the way humans do," Nicholas said. "There's a lot of exciting information out there, but it's useless unless we can find it."

Teen Genius No. 5: Nithin Tumma

In March, Nithin Tumma won $100,000 in Intel's annual science talent search. His project could lead to a better, less toxic treatment for breast cancer. Tumma also found some potential targets for future cancer therapies. He studied the molecules operating inside cancer cells and found that by thwarting certain proteins, doctors might be able to slow the growth of those cells and make them less deadly. He's 18 and hails from the Detroit area.

Teen Genius No. 6: Andrey Sushko

Don't tell this 17-year-old that model boats are just toys.

Andrey Sushko turned his childhood hobby into a robotics breakthrough. That's how he took 2nd place in the Intel talent search and walked away with $75,000. Hailing from Richland, Wash., he designed a tiny motor that uses the surface tension of water to turn its shaft. Experts say it could help push forward the field of micro-robotics. The son of two scientists, Andrey is now collaborating with a key federal lab on ways to improve the motor.

Teen Genius No. 7: Mimi Yen

Mimi Yen's study of worm mutations won her $50,000. The 17-year-old from Brooklyn plans to attend Harvard University, with an eye toward a degree in biology. She mapped the gene that causes mutant behavior in a microscopic worm often used in research. Intel execs say Mimi's work may help scientists learn more about how genes affect variations in human behavior.


Let me close by noting that not every teen these days wastes time texting or watching reruns of the TV show Jersey Shore. Many really do get out of bed every day looking for ways to change the world. In the Era of Radical Change, a lot of them will succeed in doing exactly that.

And we'll be watching...


P.S. If you want to find a way to profit from the next generation of tech breakthroughs, the Era of Radical Change newsletter is a great place to start.

And you can't beat the price. You can get it free by clicking here.

About the Author
Michael A. Robinson is one of the top financial analysts working today. His 30-year track record as a leading tech analyst has garnered him rave reviews. The first analyst to uncover the rare earth mineral crisis, he amassed cumulative gains of 990% for his readers in just 16 months. Today he is the editor of Radical Technology Profits. He also edits the Era of Radical Change e-letter that explores "what's next" in the tech investing world. Learn more about Michael on our contributors page.


View

Source: These Teen Geniuses are on a Path to Change the World:

Tuesday, June 12, 2012

5 Ways to Spot the Next Hot Biotech Stock

June 12, 2012
By 

Source: 5 Ways to Spot the Next Hot Biotech Stock:

It's not enough to understand long- term trends, today's investors need to have the ability to move quickly, especially when it comes to biotech stocks. But here is what you need to know about biotech stocks: none of them are created equal.

For all their potential, bio tech stocks remain among the most challenging for investors like you to identify, select and earn money on.

However, with a little bit of the right guidance you can narrow your list to the stocks with the highest likely upside.

In fact, I've developed a five- point checklist of what I look at when screening biotech stocks that I'd like to share with you.

It may not be a road map. The biotech sector just isn't that easy and "x" almost never marks the spot.

But it is a great place to start if you are serious about separating the pretenders from the contenders.

Five Steps for Successful Biotech Stock Investors

As you begin to break down a potential stock consider the following as it relates to your decision.

1) Choose your niche.


Biotech is a big term and an even bigger sector. There are literally thousands of companies trying to make their move in everything from vaccines to nano-technology.

There's quite literally no way you can know everything, so stick to the parts of the sector you believe have the biggest potential.

For instance, I think some of the biggest innovations and profits will come from bio tech companies that link living systems with their digital counterparts.

So I tend to concentrate my biotech investments in companies that are exploring synthetic biology and computational bioinformatics.

To me it's a no brainer.

While there is no question that traditional bio tech will be big, over the next few years we will see the line blur very rapidly between what we need to live and how we actually live - aided by technology.

Admittedly, I have a rather selfish reason...

Alzheimer's runs in my family so in a way I'm chasing my own gremlins. You may or may not be chasing yours.

Point is, choose a niche you have an interest in and learn everything you can about it.


2) Stick to companies with the "right" kind of debt.

This one is tricky because obviously debt is a loaded word right now. With governments spending trillions on completely misguided bailouts, it's easy to forget that debt can also be used to generate profits, particularly in early stage companies. When you think about it this makes sense. The average medical tech company, for example, now spends tens of millions simply getting their drug ready for laboratory testing. Add to that millions more in human trials where maybe - just maybe - the drug will be approved.


Then there is the time. Often times the process takes a decade or more after the initial development. As onerous as this sounds, keep in mind that it's against a revenue stream that could literally be in the billions. Come up with a blockbuster, and you can be in fat city for years. What's a blockbuster? I define that as a drug or technology that could potentially generate sales in excess of a billion dollars a year.


But back to the debt. What you want to see in a biotech company is steady funding. Conversely, companies that attract an initial investment then burn quickly through it without being able to gather more funding are one shot wonders. With companies like that you might as well go to Vegas.

But if the debt comes as part of an overall set of progress payments in exchange for specific developmental milestones, that's a very different case indeed. Take MicroMet for instance. It's a story about what can happen when a bidding war develops around progressive developmental payments for a promising group of therapies---in this case cancer immunotherapies.


Amgen (Nasdaq: AMGN) ultimately swallowed MicroMet for $1.16 billion, handing investor s the opportunity to capture 61.83% in the process. I know, because my readers were among them.

3) Understand that volatility is part of the package.

Just like debt, understand that there is good volatility and bad volatility. Biotech companies with bad volatility tend to move wildly yet are still generally correlated to the markets. This suggests that they really don't have too much going for them. The true winners often move independently of broader market conditions. Not always mind you, but enough that you can screen for a kind of "anti-correlation" for lack of a better term.

This can be hard to do because many promising bio-tech companies have very small market capitalizations and even smaller daily trading volume. It means you need to look behind the numbers to see if you can account for the price swings. Are insiders buying or selling? Or, has an institution stepped up with the sort of payment "plan" investment I've just referenced?

Many times the big pharma companies will set up a series of structured investments that keep them off the radar while simultaneously keeping values low enough to represent a solid risk/reward ratio. Their thinking is sound. After all, why tip off the markets when that makes a sweetheart deal more expensive for them?

Be cognizant of the story behind the story.

4) Spread your risks.

Bio tech investors need to recognize that the odds are stacked against them from the get go. While that doesn't necessarily mean you will lose, the odds of winning depend on carefully placing your bets and maintaining an adequate book. You really can't adequately play unless you're willing to put at least $5,000 on the table and be comfortable with the idea you may lose 90% of it before one of the choices you make pays off. Michael Milken of Drexel Burnham Lambert famously used to use this strategy back in the late 1980s with junk bonds. He'd buy 100 of them knowing full well that 98% would blow up and that the 1-2% that hit would hit so big he could laugh all the way to the bank.

His compensation was more than $1 billion in a four year period-- - a new record at the time according to the NY Times. It's worth noting that he had only four losing months in 17 years spent trading. Today he's heavily involved in medical research presumably for the same reasons we are...because they hold great promise.

5) Look for the Jolly Roger

Recent venture capitalist estimates suggest that life sciences investments may fall to only $2.5 billion in 2012. This is because many VC funding sources have been burned over the past few years. Instead of crying me a river, you can use that to your advantage. VC firms are like a bunch of modern pirates in that they go where the money is. That's why you want to figure out where they've hoisted the financial equivalent of a "Jolly Roger."

Right now buyouts are hot. Limited partners--a.k.a venture capitalists--won't take on new investments unless they see a path to liquidity in five years or less. That includes a buyout by a major pharma or tech company or a licensing deal from one of the same. In other words, VC firms want to identify their exit strategy before they take a stake and put up the funding.

It only stands to reason that if you can tie a specific VC to the areas in which you are interested in and even more specifically to a particular company then you've got a good shot at a picking a winner. As for IPOs, they are not the magic ticket they used to be. In the wake of the botched Facebook IPO, the public has only learned to distrust the process. At the end of the day though, for all its difficulties, investing in biotech can be one of the single biggest roads to profitability.

Just make sure you've got an idea where you're headed and a rock solid grasp on risk management. The last thing you want to do is blow your money on a promise that really isn't there.


Related Articles and News:


Tags: , , , , , ,

Pattern of the Day (Nasdaq 100)

By Scott Pluschau
source: http://scottpluschau.blogspot.com:

It is impossible to point these patterns out before hand on the blog.  I have been getting away from this type of posting.  Since I posted an intraday pattern on gold today I thought I should mention yesterday's pattern on the Nasdaq 100 futures.

There was a textbook "Bear Flag" on the 30 minute chart (see left hand side below) with the "Measured Rule" target nailed for $600+ per contract.  The saying is the "flag flies at half mast".  Notice the flag pole or mast was on strong volume, with diminishing volume in the flag, and a pickup in volume on the breakdown, which increases the probabilities of continuing supply toward the initial profit taking target in my experience. 

The flag portion of the pattern forms due to over anxious buyers, either looking for a discount and a bounce too early, or with losing traders averaging down.  This is a pattern of distribution. 

I know I wouldn't ignore this pattern, and it doesn't matter to me what "wave", "level of Fibonacci retracement", "regression channel", "moving average crossover", "standard deviation band" or some "oscillator" is reading.

(click on chart to expand)


twitter/ScottPluschau
Consulting? ScottPluschau@gmail.com
Members to Scott's blog are appreciated


Thursday, June 7, 2012

Cybersecurity Stocks: Four Ways to Play the "Flame" Attack on Iran

 
Iran loves to rattle its saber-especially when it comes to Israel.

But the country that would like to wipe Israel off the map now finds itself the target of a very different kind of war.

On the frontlines of cyberspace, Iran has become the victim of another massive attack on its computer networks.

In the wake of the Stuxnet attack, the Flame virus unleashed on Iran is one of the worst pieces of malware ever to hit cyberspace.

The Flame virus is not just nasty, it's also very smart.

It was written to spy on a user's infected system and steal data. This includes documents, recorded conversations and even keystrokes.

Then it throws open a back door that allows hackers to tweak the code giving Flame even more ways to wreak havoc.

Clearly, news of the Flame attack comes at a key moment.

Rising tensions between the U.S. and Iran over its nuclear program have left the region under the threat of a wider conventional war.

In the background is the Israeli wild card. Israel has taken key political actions to ensure it's ready if it needs to attack Iran.

Flame's success is that it helps to keep a lid on this brewing powder keg.

In short, it is war by other means-even though Israel and the U.S. both deny they are behind the Flame attacks.

Yet, there's no question the Flame episode is part a major global trend that has put cybersecurity stocks back in the public eye.

And in a moment I'll show you four ways to invest in this growing field-pegged at about $65 billion.

But first, I want to make sure you have the correct context...

The Growing Menace in Cyberspace

The truth is that the U.S. is all too often on the receiving end of cyberattacks.

Hackers from around the world try to steal or destroy sensitive defense and financial data hundreds of times a day.

Not only that, the Pentagon maintains an active Cyber Command. The unit trains around the clock to keep the nation prepared to defend against hacks.

And for good reason...

There's just no question that in what I call the Era of Radical Change, a "Cyber Cold War" is a fact of life.

You see, rogue nations and freelance hackers can easily afford to create and launch weapons of mass computer destruction.

Compared to the cost of a fighter jet or battleship, writing computer code is practically free.

In the case of Iran, this is the second major cyberattack in the past two years. In 2010, the Stuxnet worm disabled machinery for several months that Iran needs for its nuclear program.

But Flame puts Stuxnet to shame. After all, the file itself is 20 times larger and far more complex.

It can turn a computer into a wireless vacuum cleaner. It sucks up names and phone numbers from nearby devices and transfers them back to the attacker's server.

Though Iran is not the only target, Flame has mostly focused on the Middle East. Other countries fending off Flame include Egypt, Israel, Lebanon, Saudi Arabia, Sudan and Syria.

In all, the Flame virus has attacked nearly 600 systems.

Four Ways to Invest in Cybersecurity Stocks

Clearly, news like this means investors need to keep an eye on cybersecurity stocks. Several have gotten slammed in the market's recent retreat but offer good long-term opportunities.

Take the case of Fortinet, Inc. (Nasdaq: FTNT). Trading at about $20, the stock is off more than 20% in the past month. And the price may get even better because tech stocks have come under pressure of late. With a market cap of $3.2 billion, it has a 14% profit margin and earns 19% on equity. It has $428 million in cash and no debt.

Fast-growing Sourcefire, Inc. (Nasdaq: FIRE) also has gotten slammed. It's down more than 12% in the past month. Yet FIRE has $150 million in cash and no debt. However, Sourcefire can't match Fortinet's solid margins.  With a market cap of about $1.5 billion, Sourcefire returns just 3% on equity. But the company does have 2,500 clients in 180 countries and boasts 41 pending or actual patents.

Shares of Check Point Software Technologies Ltd. (Nasdaq: CHKP) also got caught in the May rout, ending the month off by about 13%. But the balance sheet looks great. Check Point has a market cap of about $10.4 billion. Selling at about $50, it trades at just 14 times forward earnings. It has an operating profit margin of more than 50 percent with $1.4 billion in cash and no debt.

Then there is small cap KEYW Holding Corp. (Nasdaq: KEYW). It trades at just $9. Though it's off slightly in the past 30 days, KEYW has beaten its larger rivals over the past three months. For the quarter, KEYW returned 29% to shareholders compared with 11.5% for FIRE and declines of 15% for CHKP and 26% for FTNT. The point is that we have millions of computers around the world connected to either the Web or private networks. For hackers, these computer networks are a target-rich landscape.

That means cybersecurity will remain an active field for investors for at least the next several years. And to help you stay abreast these growing cyber threats and other cutting-edge high tech, I recently launched the Era of Radical Change.  It is a free newsletter that will show you how to profit from the most important trends reshaping the world around us.

I'm referring to things like:
  1. A mini robot that charges your cell phone just by hovering over it.
  2. How a new app can turn your smart phone into a bomb detector and send an alert to the police.
  3. And an exotic new material that's the thickness of a single atom. Someday, it will give us TV screens that are slimmer than a sheet of paper.
So, if you want to find a way to profit from the next generation of tech breakthroughs, the Era of Radical Change is a great place to start.

And you can't beat the price. You can get it free by clicking here.

source: http://moneymorning.com/2012/06/06/cybersecurity-stocks-four-ways-to-play-the-flame-attack-on-iran/

Tuesday, June 5, 2012

Apple Watch: Patent Wars

In a single stroke, Apple Inc. (Nasdaq: AAPL) could gain the upper hand in its seemingly endless patent wars with Samsung Electronics (PINK: SSNLF) and others.

Or the tech giant could blow its chance and wind up paying billions of dollars in licensing fees.

The outcome hinges on how Apple deals with a little-known company based in Sweden.

This micro-cap just happened to file a patent for the "swipe-to-unlock" touchscreen gesture in 2002 - three years before Apple filed its patent.

The company, Neonode (Nasdaq: NEON), received its U.S. patent in January.

Neonode holds a number of touchscreen-related patents that could become decisive in several of Apple's mobile computing patent cases.

Already the "swipe-to-unlock" patent helped Samsung defeat Apple in a recent patent case in the Netherlands. Samsung said the patent, as well as a phone Neonode released in 2005, represented "prior art."

"Apple just shot itself in the foot and all the blood is going to go to NEON," Jim Altucher, managing director of Formula Capital and well-known investor, wrote in a blog post Tuesday evening.

Insiders told The Wall Street Journal in April that Samsung plans to use the Neonode patent in a similar but much more crucial case in San Jose, CA, scheduled for a July trial.

And Altucher added a scarier prospect for Apple.

If Neonode does indeed hold the patent trump card for "swipe-to-unlock," it could gun for a cut of Apple's profits by filing its own patent case.

Should Apple be forced to fork over licensing fees to Neonode, it could cost the Cupertino, CA, company billions of dollars a year.

So far all this sounds like a big mess for AAPL and a big opportunity for its patent war rivals. Not just Samsung, but also for such titans as Google Inc. (Nasdaq: GOOG) and Microsoft Corp. (Nasdaq: MSFT).

Yet if Apple acts boldly, it could gain a crucial advantage on its mobile computing competitors.

How Apple Can Win the Patent Wars

What could Apple do? Well, it could consider a licensing agreement with Neonode.

Neonode's head of IP, Yossi Shain, told TechCrunch in February it was seeking licensing deals for the "swipe-to-unlock" patent and planned to contact Apple.

But the truth is such a deal would be of limited benefit to Apple. Neonode's business model is to make non-exclusive licensing agreements for its technology, so Android device makers would have equal access to the same patents.

Without exclusive control of those key patents, many of Apple's patent cases would crumble. That's what happened in the Netherlands.

So Apple needs to buy Neonode, and the sooner the better. Not only would that avoid the need to pay Neonode, it would strengthen Apple's hand in the patent wars.

Apple can easily afford NEON, even at a steep premium. Neonode stock currently trades at about $6 with a market cap just under $200 million.

And because Neonode is based outside the U.S., Apple could use some of its $74 billion in foreign-based cash to pay for it. With that kind of money, Apple could pay 10 times Neonode's valuation - about $2 billion - and hardly miss it.

In any event, buying NEON would almost certainly be cheaper than paying it licensing fees.

But most importantly, Apple needs to buy Neonode to prevent its rivals from snatching those key patents. Microsoft, Google and Samsung - each well-heeled in its own right -- would love to have them.

"One of these companies is going to have to buy NEON to get a hold of the original patents," Altucher wrote. "Not only did NEON patent the swipe-to-unlock but they patented many of the touch-sense technologies we use on tablet devices."

What the Neonode Patents Mean For Investors

For investors, the Neonode situation raises a caution flag on Apple. Should Google or Samsung snap up Neonode, the balance of power in the patent wars will shift away from Apple in a major way.

It's hard to predict just how much harm that would do to Apple's business. But the company uses those touchscreen patents in its iPad, iPhone and iPod Touch products, which together generate more than three-fourths of Apple's revenue.

Far more interesting is what this development means for tiny Neonode.

In his blog post, Altucher contends that Apple's dire position relative to the Neonode patents is "more than enough to drive NEON to $30."

Not surprisingly, Altucher's post pushed the stock up 28% in Wednesday trading.

But an acquisition is not all NEON has going for it. Neonode already has e-reader patent licensing deals with such companies as Amazon.com (Nasdaq: AMZN), Sony Corp. (NYSE: SNE) and Barnes & Noble Inc. (NYSE: BKS).

And in April Neonode announced 17 design wins where the company helped customers integrate its technology with their products. Altucher suspects some of these undisclosed products may include household appliances and auto touch panels.

Earnings for the March quarter were a mixed bag. Revenue rose 100%, while the cost of that revenue rose 61% and Neonode posted a loss of 5 cents a share.

But guidance was positive, with the company forecasting revenue of $18 million-$20 million. Revenue for the March quarter was $1.2 million.

While Neonode's prospects look tempting, particularly if it can execute, investors should note that its small market cap and low float do make it more risky and volatile.

In addition, NEON only just started trading on the NASDAQ May 1; before that it was an OTC stock. It's also worth noting that Neonode's phone-making arm declared bankruptcy in 2008.

Nevertheless, Altucher, who owns Neonode stock, accentuated the positive in his piece.

"A competitive technology can always be developed, but NEON has the significant advantage of having patents, clients in every sector, and having been through the multi-year cycles to get these design wins," he wrote.

Source: http://moneymorning.com/2012/06/04/apples-nasdaq-aapl-patent-wars-this-little-known-swedish-company-is-the-key/